CD93 and acute myeloid leukemia: Richards et al. demonstrated that CD93 CAR T cells, engineered with a novel humanized CD93-specific binder, effectively target and eliminate AML cells both in vitro and in vivo, while sparing hematopoietic stem and progenitor cells (HSPCs) [196].